分享产品介绍 评论(0)
物种
Human分子别名
CD300g, Nepmucin, CLM9Accession
Q6UXG3-1表达序列
Leu19-Arg247, with C-terminal hIgG Fc表达宿主
HEK293分子量
75-90kDa (Reducing)纯度
＞95% by SDS-PAGE内毒素含量
<0.1EU/μg标记
Unconjugated标签
Human Fc Tag性状
Lyophilized Powder缓冲体系
PBS, pH7.4.溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.储存条件
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.文献引用
1. Soojung Jin. Nepmucin/CLM-9, an Ig domain-containing sialomucin in vascular endothelial cells, promotes lymphocyte transendothelial migration in vitro. FEBS Lett. 2008 Sep 3;582(20):3018-24. Epub 2008 Aug 4.
Nepmucin/CLM-9 is an Ig domain-containing sialomucin expressed in vascular endothelial cells. Here we show that, like CD31, nepmucin was localized to interendothelial contacts and to vesicle-like structures along the cell border and underwent intracellular recycling. Functional analyses showed that nepmucin mediated homotypic and heterotypic cell adhesion via its Ig domain. Nepmucin-expressing endothelial cells showed enhanced lymphocyte transendothelial migration (TEM), which was abrogated by anti-nepmucin mAbs that block either homophilic or heterophilic binding. Notably, the mAbs that inhibited homophilic binding blocked TEM without affecting lymphocyte adhesion. These results suggest that endothelial nepmucin promotes lymphocyte TEM using multiple adhesion pathways.
电泳
1μg (R: reducing condition, N: non-reducing condition).
评论(0)